Preliminary Communication

Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma: a preliminary study

*Author for correspondence: Tel.: +48 42 272 56 88;

Department of Medical Biochemistry, Medical University of Lodz, Mazowiecka Street 6/8 92–215 Lodz, Poland

Department of Biochemistry, Faculty of Agriculture & Biology, Warsaw University of Life Sciences – SGGW, Nowoursynowska Street 159, 02–776 Warsaw, Poland

^‡Authors contributed equally

Search for more papers by this author

Anna Bielecka-Kowalska^‡

Non-public Medical Center ‘Akoria’, Rydzowa Street 22, 92–157 Lodz, Poland

^‡Authors contributed equally

Search for more papers by this author

Michał Seweryn Karbownik

Department of Pharmacology & Toxicology, Medical University of Lodz, Zeligowskiego Street 7/9, 90–752 Lodz, Poland

Search for more papers by this author

Radzisław Kordek

Department of Pathology Chair of Oncology, Medical University of Lodz, Pomorska Street 251, 92–213 Lodz, Poland

Search for more papers by this author

Maciej Jabłkowski

Department of Infectious & Liver Diseases, Medical University of Lodz, Kniaziewicza Street 1/5, 91–347 Lodz, Poland

Search for more papers by this author

Janusz Szemraj

Department of Medical Biochemistry, Medical University of Lodz, Mazowiecka Street 6/8 92–215 Lodz, Poland

BioNanoPark Laboratories, Lodz Regional Park of Science & Technologies, Dubois Street 114/116, 93-465, Lodz, Poland

Search for more papers by this author

Published Online:11 Mar 2019https://doi.org/10.2217/bmm-2018-0485

View article

Abstract

Aim: To assess the diagnostic value of selected miRNAs from various material collected from hepatocellular carcinoma (HCC) patients. Patients & methods: Tissue, serum, urine and fecal samples from HCC patients and healthy individuals were screened for associated miRNAs using microarray analysis; the selected miRNAs were then validated by real time-quantitative PCR on 65 patients. Results: Serum miR-122, a combination of serum miR-155 with miR-885-5p, a combination of urinary miR-532-3p with miR-765, and fecal miR-320a displayed 100% efficiency in discriminating patients from controls. A combination of urinary miR-532-3p and miR-765 allowed patients with neoplastic grade G3 to be distinguished from those with G1 and G2. Conclusion: Additionally to serum, urine and feces also appeared to be valuable source of potential HCC noninvasive miRNA biomarkers.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), e359–e386 (2015).
Medline CASGoogle Scholar
2 Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: a systematic review. Hepatol. Res. 46(5), 391–4062014.
Google Scholar
3 Marra M, Sordelli IM, Lombardi A et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J. Transl. Med. 9(1), 171 (2011).
Medline CASGoogle Scholar
4 Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes mechanism of progression and biomarkers. Curr. Chem. Genom. Transl. Med. 12, 9–26 (2018). • Summarizes the current knowledge about hepatocellular carcinoma (HCC) and HCC biomarkers.
Medline CASGoogle Scholar
5 D'Anzeo M, Faloppi L, Scartozzi M et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules 19(5), 6393–6406 (2014). • Shows the role of miRNAs in HCC.
MedlineGoogle Scholar
6 Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8(8), 467–477 (2011).
Medline CASGoogle Scholar
7 Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9(2), 102–114 (2008). • Summarizes the basic knowledge about mechanism of miRNAs regulation of gene expression.
Medline CASGoogle Scholar
8 Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10(10), 704–714 (2009).
Medline CASGoogle Scholar
9 Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257–2261 (2006).
Medline CASGoogle Scholar
10 Zhang Y, Xu Z, Zhang T, Wang Y. Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J. Gastroenterol. 21(34), 9853–9862 (2015).
Medline CASGoogle Scholar
11 Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513–10518 (2008). •• Summarizes the role of circulating miRNAs in cancer diagnosis.
Medline CASGoogle Scholar
12 Schmittgen T, Livak K. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3(6), 1101–1108 (2008). • Describes the comparative CT method for real time-quantitative PCR data analysis.
Medline CASGoogle Scholar
13 Xue X, Zhao Y, Wang X, Qin L, Hu R. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. J. Cell Biochem. 120(1), 135–142 (2018).
MedlineGoogle Scholar
14 Zekri AN, Youssef SE, El-Desouky ED et al. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol. 37(9), 12273–12286 (2016).
Medline CASGoogle Scholar
15 Khairy A, Hamza I, Shaker O, Yosry A. Serum miRNA panel in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 17(5), 2699–2703 (2016).
MedlineGoogle Scholar
16 Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB. Serum miR-30e and miR-223 as novel noninvasive biomarkers for hepatocellular carcinoma. Am. J. Pathol. 186(2), 242–247 (2016).
Medline CASGoogle Scholar
17 Bronte F, Bronte G, Fanale D et al. HepatomiRNoma: the proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit. Rev. Oncol. Hematol. 97, 312–321 (2016).
MedlineGoogle Scholar
18 Yin J, Hou P, Wu Z, Wang T, Nie Y. Circulating miR-375 and miR-199a-3p as potential biomarkers for the diagnosis of hepatocellular carcinoma. Tumour Biol. 36(6), 4501–4507 (2015).
Medline CASGoogle Scholar
19 Zhang GL, Li XY, Zheng SQ, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 88(2), 169–175 (2010).
Medline CASGoogle Scholar
20 Xing TJ, Jiang DF, Huang JX, Xu ZL. Expression and clinical significance of miR-122 and miR-29 in hepatitis B virus-related liver disease. Genet. Mol. Res. 13(3), 7912–7918 (2014).
Medline CASGoogle Scholar
21 Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microrna biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C Virus Egyptian patients. J. Cancer 3, 19–31 (2012). •• Shows the potential of urinary miRNAs in HCC diagnosis.
Medline CASGoogle Scholar
22 Wang Y, Yang Z, Wang L et al. miR-532-3p promotes hepatocellular carcinoma progression by targeting PTPRT. Biomed. Pharmacother. 109, 991–999 (2019).
Medline CASGoogle Scholar
23 Pospisilova S, Pazourkova E, Horinek A et al. MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. Neoplasma 63(5), 799–808 (2016).
Medline CASGoogle Scholar
24 Xie BH, He X, Hua RX et al. Mir-765 promotes cell proliferation by downregulating INPP4B expression in human hepatocellular carcinoma. Cancer Biomark. 16(3), 405–413 (2016).
Medline CASGoogle Scholar
25 Yao J, Liang L, Zhang Y et al. GNAI1 suppresses tumor cell migration and invasion and is post-transcriptionally regulated by mir-320a/c/d in hepatocellular carcinoma. Cancer Biol. Med. 9(4), 234–241 (2012).
Medline CASGoogle Scholar
26 Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z. miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem. Funct. 31(1), 82–85 (2013).
Medline CASGoogle Scholar
27 Zhang Y, Zheng L, Ding Y et al. MiR-20a induces cell radioresistance by activating the PTEN/PI3K/Akt signaling pathway in hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 92(5), 1132–1140 (2015).
Medline CASGoogle Scholar
28 Wen Y, Han J, Chen J et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int. J. Cancer 137(7), 1679–1690 (2015).
Medline CASGoogle Scholar
29 Chen Y, Dong X, Yu D, Wang X. Serum miR-96 is a promising biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Int. J. Clin. Exp. Med. 8(10), 18462–18468 (2015).
Medline CASGoogle Scholar
30 Ahmed FE, Ahmed NC, Vos PW et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 10(20), 93–113 (2013). •• Shows the potential of fecal miRNAs in cancer diagnosis.
Medline CASGoogle Scholar
31 Yau TO, Wu CW, Tang CM et al. microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. Oncotarget 7(2), 1559–1568 (2016).
MedlineGoogle Scholar
32 Connolly EC, Van Doorslaer K, Rogler LE, Rogler CE. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol. Cancer Res. 8(5), 691–700 (2010).
Medline CASGoogle Scholar
33 Ji J, Yamashita T, Budhu A et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50(2), 472–480 (2009).
Medline CASGoogle Scholar
34 Zhang L, Wang W, Li X et al. MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2. Int. J. Oncol. 48(6), 2425–2434 (2016).
Medline CASGoogle Scholar
35 Yuan Q, Loya K, Rani B et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 57(1), 299–310 (2013).
Medline CASGoogle Scholar
36 Lu C, Liao Z, Cai M, Zhang G. MicroRNA-320a downregulated mediates human liver cancer cell proliferation through the Wnt/β-catenin signaling pathway. Oncol. Lett. 13(2), 573–578 (2016).
MedlineGoogle Scholar
37 Shyu YC, Lee TL, Lu MJ et al. miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma. J. Transl. Med. 14(1), 200 (2016).
MedlineGoogle Scholar
38 Jin B, Wang W, Meng XX et al. Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway. BMC Cancer 16(1), 863 (2016).
MedlineGoogle Scholar
39 Qiu D, Chen J, Liu J et al. Expression of microRNA let-7a positively correlates with hepatitis B virus replication in hepatocellular carcinoma tissues. Exp. Biol. Med. 242(9), 939–944 (2017).
CASGoogle Scholar
40 Yu SL, Deng H, Li XH, Huang YX, Xie DY, Gao ZL. Expression of microRNA-155 is downregulated in peripheral blood mononuclear cells of chronic hepatitis B patients. Hepat. Mon. 16(1), e34483 (2016).
MedlineGoogle Scholar
41 Wang WJ, Lai RT, Lu J et al. Correlation between circulating miR-122 and prognosis of chronic HBV-related liver failure. J. Dig. Dis. 17(5), 334–339 (2016).
Medline CASGoogle Scholar
42 Elfil M, Negida A. Sampling methods in clinical research; an educational review. Emergency 5(1), e52 (2017).
MedlineGoogle Scholar
43 Zhang F, Ding L, Cui Li, Barber R, Deng B. Identification of long non-coding RNA-related and -coexpressed mRNA biomarkers for hepatocellular carcinoma. BMC Medical Genomics 12(Suppl. 1), 25 (2019).
MedlineGoogle Scholar

Vol. 13, No. 7

Metrics

Downloaded 128 times

History

Received 21 December 2018

Accepted 21 February 2019

Published online 11 March 2019

Published in print May 2019

Information

Keywords

Author contributions

WZ Świtlik and A Bielecka-Kowalska prepared the manuscript, analyzed the results and carried out the experiments. MS Karbownik performed the statistical analysis and helped with manuscript preparation. R Kordek conceived the study, supervised the project and revised the final manuscript. M Jabłkowski was responsible for the study design, sample collection and preparation, helped with manuscript preparation. J Szemraj carried out the experiments, conceived and designed the study, supervised the project and revised the final manuscript.

Financial & competing interests disclosure

This work was supported by the National Science Center (grant number UMO-2012/05/B/NZ5/01852) and research project grant from the Medical University of Lodz (grant number 502-64-107). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The collection of tumor tissues, adjacent normal liver tissues, blood, urine and feces was performed in accordance with the protocols approved by the Bioethics Committee of the Medical University of Lodz. The authors state that this study was performed in accordance with the protocols approved by the Committee of Bioethics of the Medical University of Lodz (RNN/228/11/KE). Informed consent was obtained from all individual participants included in the study in accordance with the Declaration of Helsinki.

PDF download